Published in Circulation on April 19, 2011
A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet (2011) 1.48
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation (2012) 1.26
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Mapping genes that predict treatment outcome in admixed populations. Pharmacogenomics J (2010) 1.05
Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift. Indian J Pharm Sci (2015) 0.95
Pharmacogenomics: will the promise be fulfilled? Nat Rev Genet (2010) 0.92
An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care. PLoS One (2014) 0.91
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clin Pharmacol Ther (2016) 0.86
Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J (2013) 0.84
Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet (2011) 0.84
Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J Hum Genet (2016) 0.83
Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. Pharmacogenomics J (2015) 0.81
To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation. Circ Cardiovasc Genet (2013) 0.81
Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet (2015) 0.77
Genes and Cardiovascular Disease: Where do we go from here? Sultan Qaboos Univ Med J (2015) 0.75
Role of genomics in eliminating health disparities. J Carcinog (2015) 0.75
Finding the missing heritability of complex diseases. Nature (2009) 67.95
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
A HapMap harvest of insights into the genetics of common disease. J Clin Invest (2008) 18.31
A comprehensive review of genetic association studies. Genet Med (2002) 16.75
Replication validity of genetic association studies. Nat Genet (2001) 16.30
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Genetic control of isoniazid metabolism in man. Br Med J (1960) 7.86
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 5.48
Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 5.43
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 3.69
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol (2009) 3.10
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov (2004) 2.96
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med (2001) 2.74
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm (2007) 2.62
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation (2003) 2.42
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther (2009) 2.04
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet (2008) 1.99
Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther (2003) 1.96
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94
A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet (2009) 1.78
Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation (2001) 1.76
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation (2008) 1.64
Combinatorial pharmacogenetics. Nat Rev Drug Discov (2005) 1.58
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol (1982) 1.52
Pharmacogenetics--tailoring treatment for the outliers. N Engl J Med (2009) 1.50
Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther (2004) 1.49
Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet (2005) 1.48
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol (2008) 1.46
Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther (2009) 1.44
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation (2009) 1.41
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics (2005) 1.38
The hemolytic effect of primaquine. VI. An in vitro test for sensitivity of erythrocytes to primaquine. J Lab Clin Med (1955) 1.37
A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther (2003) 1.34
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail (2009) 1.25
Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos (2001) 1.23
Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook. N Engl J Med (2009) 1.23
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Repolarization reserve: a moving target. Circulation (2008) 1.20
Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry (2009) 1.09
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension (2001) 1.07
Clopidogrel and the concept of high-risk pharmacokinetics. Circulation (2009) 1.06
Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther (2009) 1.05
A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. Br J Clin Pharmacol (2008) 0.91
Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther (1995) 0.91
High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J Hum Genet (2007) 0.86
Proceedings: N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.85
Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation (2010) 0.83
Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther (2009) 0.78
Polymorphisms of N-acetyltransferase genes. Xenobiotica (1992) 0.78
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med (2009) 7.89
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 5.17
Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 4.58
Cohort profile: the study of health in Pomerania. Int J Epidemiol (2010) 4.38
New drugs for rheumatoid arthritis. N Engl J Med (2004) 4.38
Clinical practice. Long-QT syndrome. N Engl J Med (2008) 4.05
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet (2011) 3.85
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum (2005) 3.17
Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA (2013) 3.15
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol (2006) 3.10
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 2.49
Quality control procedures for genome-wide association studies. Curr Protoc Hum Genet (2011) 2.48
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46
Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One (2010) 2.43
Reform of drug regulation--beyond an independent drug-safety board. N Engl J Med (2006) 2.17
Blacks have a greater sensitivity to α1-adrenoceptor-mediated venoconstriction compared with whites. Hypertension (2013) 2.13
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis (2006) 2.00
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood (2008) 1.99
CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther (2004) 1.99
A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf (2010) 1.97
Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry (2013) 1.95
Comment on "A common genetic variant is associated with adult and childhood obesity". Science (2007) 1.93
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes (2009) 1.90
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev (2002) 1.86
A genome-wide association study of metabolic traits in human urine. Nat Genet (2011) 1.84
The aprotinin story--is BART the final chapter? N Engl J Med (2008) 1.84
Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology (2007) 1.80
Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum (2005) 1.80
Importance of multi-modal approaches to effectively identify cataract cases from electronic health records. J Am Med Inform Assoc (2012) 1.79
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics (2004) 1.75
Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics (2002) 1.75
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis (2007) 1.73
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
Genome-wide association analysis identifies multiple loci related to resting heart rate. Hum Mol Genet (2010) 1.67
Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol (2007) 1.64
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum (2008) 1.63
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis (2009) 1.63
Intraocular pressure response to topical beta-blockers associated with an ADRB2 single-nucleotide polymorphism. Arch Ophthalmol (2008) 1.57
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum (2009) 1.56
A new, accurate predictive model for incident hypertension. J Hypertens (2013) 1.53
Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos (2010) 1.53
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis. J Am Coll Cardiol (2013) 1.50
Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics (2004) 1.47
MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol (2007) 1.45
Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum (2009) 1.45
Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J (2012) 1.44
Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks. PLoS One (2011) 1.42
The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42
Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther (2004) 1.41
Stereoselective disposition of talinolol in man. J Pharm Sci (2002) 1.40
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics (2007) 1.39
Cardiovascular toxicity of valdecoxib. N Engl J Med (2004) 1.39
Population Pharmacokinetics of Fentanyl in the Critically Ill. Crit Care Med (2016) 1.39
Biobanking and pharmacogenomics. Pharmacogenomics (2010) 1.36
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm (2009) 1.33
Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther (2006) 1.31
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet (2011) 1.30
Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol (2011) 1.26
Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol (2008) 1.24
Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiol Drug Saf (2008) 1.23
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther (2002) 1.23
Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol (2010) 1.23
Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos (2006) 1.22
Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev (2005) 1.22
Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res (2009) 1.21
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat (2008) 1.21
Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol (2010) 1.15
The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood (2004) 1.15
An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf (2011) 1.14
Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos (2005) 1.14
Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Hum Mol Genet (2012) 1.14
High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin Transl Sci (2012) 1.13
Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. Eur Radiol (2012) 1.13
Characterization of the human myocardial proteome in inflammatory dilated cardiomyopathy by label-free quantitative shotgun proteomics of heart biopsies. J Proteome Res (2011) 1.12
Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol (2009) 1.11
Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther (2006) 1.11
Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol (2006) 1.10
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet (2011) 1.10
Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus (2009) 1.10